Expression analysis in lung cancer: The search for biomarkers

American Journal of Respiratory Cell and Molecular Biology

Volumn 31, Issue 2 II, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ILOPROST;

CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DNA MICROARRAY; DRUG RESPONSE; DRUG SCREENING; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE PROBE; GENETIC ANALYSIS; GENETIC REGULATION; GENOME ANALYSIS; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; LUNG CANCER; LUNG CARCINOMA; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MULTIGENE FAMILY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; SCREENING; VALIDATION PROCESS;

EID: 4143106875     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Sugita, M., M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, and W. A. Franklin. 2002. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 62:3971-3979.
2. Bhattacharjee, A., W. G. Richards, J. Staunton, C. Li, S. Monti, P. Vasa, C. Ladd, J. Beheshti, R. Bueno, M. Gillette, M. Loda, G. Weber, E. J. Mark, E. S. Lander, W. Wong, B. E. Johnson, T. R. Golub, D. J. Sugarbaker, and M. Meyerson. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 98:13790-13795.
3. Li, H., and Y. Luan. 2003. Kernel Cox regression models for linking gene expression profiles to censored survival data. Pac. Symp. Biocomput. 65-76.
4. Beer, D. G., S. L. Kardia, C. C. Huang, T. J. Giordano, A. M. Levin, D. E. Misek, L. Lin, G. Chen, T. G. Gharib, D. G. Thomas, M. L. Lizyness, R. Kuick, S. Hayasaka, J. M. Taylor, M. D. Iannettoni, M. B. Orringer, and S. Hanash. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:816-824.
5. Chen, G., T. G. Gharib, H. Wang, C. C. Huang, R. Kuick, D. G. Thomas, K. A. Shedden, D. E. Misek, J. M. Taylor, T. J. Giordano, S. L. Kardia, M. D. Iannettoni, J. Yee, P. J. Hogg, M. B. Orringer, S. M. Hanash, and D. G. Beer. 2003. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 100:13537-13542.
6. Yanagisawa, K., Y. Shyr, B. J. Xu, P. P. Massion, P. H. Larsen, B. C. White, J. R. Roberts, M. Edgerton, A. Gonzalez, S. Nadaf, J. H. Moore, R. M. Caprioli, and D. P. Carbone. 2003. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433-439.
7. Kikuchi, T., Y. Daigo, T. Katagiri, T. Tsunoda, K. Okada, S. Kakiuchi, H. Zembutsu, Y. Furukawa, M. Kawamura, K. Kobayashi, K. Imai, and Y. Nakamura. 2003. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192-2205.
8. Whiteside, M. A., D. T. Chen, R. A. Desmond, S. A. Abdulkadir, and G. L. Johanning. 2004. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 23:744-752.
9. Taxman, D. J., J. P. MacKeigan, C. Clements, D. T. Bergstralh, and J. P. Ting. 2003. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res. 63:5095-5104.
10. Marcus, P. M., E. J. Bergstralh, R. M. Fagerstrom, D. E. Williams, R. Fontana, W. F. Taylor, and P. C. Prorok. 2000. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J. Natl. Cancer Inst. 92:1308-1316.
11. Mountain, C. F. 1997. Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717.
12. Mountain, C. F. 2002. Staging classification of lung cancer: a critical evaluation. Clin. Chest Med. 23:103-121.
13. Malkinson, A. M. 2001. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 32:265-279.
14. Shimkin, M. B., and G. D. Stoner. 1975. Lung tumors in mice: application to carcinogenesis bioassay. Adv. Cancer Res. 21:1-58.
15. Malkinson, A. M. 1998. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp. Lung Res. 24:541-555.
16. McShane, L. M., M. D. Radmacher, B. Freidlin, R. Yu, M. C. Li, and R. Simon. 2002. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 18:1462-1469.
17. Radmacher, M. D., L. M. McShane, and R. Simon. 2002. A paradigm for class prediction using gene expression profiles. J. Comput. Biol. 9:505-511.
18. Tsai, J., R. Sultana, Y. Lee, G. Pertea, S. Karamycheva, V. Antonescu, J. Cho, B. Parvizi, F. Cheung, and J. Quackenbush. 2001. RESOURCERER: a database for annotating and linking microarray resources within and across species. Genome Biology http://genomebiology.eom/2001/2/II/software/0002.
19. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863-14868.
20. Balsara, B. R., and J. R. Testa. 2002. Chromosomal imbalances in human lung cancer. Oncogene 21:6877-6883.
21. Testa, J. R., Z. Liu, M. Feder, D. W. Bell, B. Balsara, J. Q. Cheng, and T. Taguchi. 1997. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet. Cytogenet. 95:20-32.
22. Ashburner, M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin, and G. Sherlock. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25:25-29.
23. Steele, V. E., E. T. Hawk, J. L. Viner, and R. A. Lubet. 2003. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat. Res. 523-524:137-144.
24. Bunting, S., R. Gryglewski, S. Moncada, and J. R. Vane. 1976. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 12:897-913.
25. Jugdutt, B. I., G. M. Hutchins, B. H. Bulkley, and L. C. Becker. 1979. Myocardial infarction in the conscious dog: three-dimensional mapping of infarct, collateral flow and region at risk. Circulation 60:1141-1150.
26. Ribeiro, L. G., T. A. Brandon, D. G. Hopkins, L. A. Reduto, A. A. Taylor, and R. R. Miller. 1981. Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am. J. Cardiol. 47:835-840.
27. Sheng, H., J. Shao, S. C. Kirkland, P. Isakson, R. J. Coffey, J. Morrow, R. D. Beauchamp, and R. N. DuBois. 1997. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99:2254-2259.
28. Hubbard, W. C., M. C. Alley, G. N. Gray, K. C. Green, T. L. McLemore, and M. R. Boyd. 1989. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 49:826-832.
29. Hara, S., A. Miyata, C. Yokoyama, H. Inoue, R. Brugger, F. Lottspeich, V. Ullrich, and T. Tanabe. 1994. Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. J. Biol. Chem. 269:19897-19903.
30. Heasley, L. E., S. Thaler, M. Nicks, B. Price, K. Skorecki, and R. A. Nemenoff. 1997. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem. 272:14501-14504.
31. Geraci, M. W., B. Gao, D. C. Shepherd, M. D. Moore, J. Y. Westcott, K. A. Fagan, L. A. Alger, R. M. Tuder, and N. F. Voelkel. 1999. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest. 103:1509-1515.
32. Korfhagen, T. R., S. W. Glasser, S. E. Wert, M. D. Bruno, C. C. Daugherty, J. D. McNeish, J. L. Stock, S. S. Potter, and J. A. Whitsett. 1990. Cis-acting sequences from a human surfactant protein gene confer pulmonary-specific gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 87:6122-6126.
33. Mirvish, S. S. 1968. The carcinogenic action and metabolism of urethan and N-hydroxyurethan. Adv. Cancer Res. 11:1-42.
34. Malkinson, A. M., K. M. Koski, W. A. Evans, and M. F. Festing. 1997. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res. 57:2832-2834.
35. Witschi, H. 1993. Modulation of tumor development by butylated hydroxytoluene in experimental animals. Toxicol. Ind. Health 9:259-281.
36. Keith, R. L., Y. E. Miller, Y. Hoshikawa, M. D. Moore, T. L. Gesell, B. Gao, A. M. Malkinson, H. A. Golpon, R. A. Nemenoff, and M. W. Geraci. 2002. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 62:734-740.
37. Lim, H., R. A. Gupta, W. G. Ma, B. C. Paria, D. E. Moller, J. D. Morrow, R. N. DuBois, J. M. Trzaskos, and S. K. Dey. 1999. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 13:1561-1574.
38. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.
39. Gupta, R. A., J. Tan, W. F. Krause, M. W. Geraci, T. M. Willson, S. K. Dey, and R. N. DuBois. 2000. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. USA 97:13275-13280.
40. He, T. C., T. A. Chan, B. Vogelstein, and K. W. Kinzler. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345.
41. Vanden Heuvel, J. P. 1999. Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J. Nutr. 129:575S-580S.
42. Oreffo, V. I., S. Robinson, M. You, M. C. Wu, and A. M. Malkinson. 1998. Decreased expression of the adenomatous polyposis coli (Apc) and mutated in colorectal cancer (Mcc) genes in mouse lung neoplasia. Mol. Carcinog. 21:37-49.
43. Tsujii, M., and R. N. DuBois. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
44. Tsujii, M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R. N. Dubois. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
45. Black, C. M., L. Halkier-Sorensen, J. J. Belch, S. Ullman, R. Madhok, A. J. Smit, J. D. Banga, and H. R. Watson. 1998. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br. J. Rheumatol. 37:952-960.
46. Hildebrand, M. 1997. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. Eur. J. Clin. Pharmacol. 53:51-56.